These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30682034)

  • 1. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
    Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG
    PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
    Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.
    Jing J; Kielstein JT; Schultheiss UT; Sitter T; Titze SI; Schaeffner ES; McAdams-DeMarco M; Kronenberg F; Eckardt KU; Köttgen A;
    Nephrol Dial Transplant; 2015 Apr; 30(4):613-21. PubMed ID: 25395390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
    Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
    Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
    Toprover M; Crittenden DB; Modjinou DV; Oh C; Krasnokutsky S; Fisher MC; Keenan RT; Pillinger MH
    Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):87-91. PubMed ID: 31140959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and variation of Chronic Kidney Disease in the Irish health system: initial findings from the National Kidney Disease Surveillance Programme.
    Stack AG; Casserly LF; Cronin CJ; Chernenko T; Cullen W; Hannigan A; Saran R; Johnson H; Browne G; Ferguson JP
    BMC Nephrol; 2014 Nov; 15():185. PubMed ID: 25425510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    Pui K; Gow PJ; Dalbeth N
    J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series.
    Albert J; Broadwell A; Padnick-Silver L; Marder B; LaMoreaux B
    Medicine (Baltimore); 2024 Mar; 103(10):e37424. PubMed ID: 38457582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.
    Loustau C; Rosine N; Forien M; Ottaviani S; Juge PA; Lioté F; Bardin T; Richette P; Dieudé P; Richez C; Bannwarth B; Schaeverbeke T; Ea HK; Truchetet ME
    Joint Bone Spine; 2018 Dec; 85(6):755-760. PubMed ID: 29654950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.
    Lee S; So MW
    Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of diminished kidney function in a representative sample of middle and older age adults in the Irish population.
    Browne GM; Eustace JA; Fitzgerald AP; Lutomski JE; Perry IJ
    BMC Nephrol; 2012 Nov; 13():144. PubMed ID: 23121733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Allopurinol on the Progression of Chronic Kidney Disease.
    Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW;
    N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.